Anand Iyer

Anand Iyer, an AI crypto investor entrenched in both industries, discusses the nascent world of decentralized AI. He tackles the stark contrast in funding—$300 billion for centralized AI versus just $1 billion for decentralized options—highlighting a massive opportunity for innovation. Anand predicts the next big project could emerge from just one developer on-chain. The conversation also dives into the ethical implications of AI in personal relationships and how blockchain can enhance privacy in this evolving tech landscape.

Shayon Sengupta, a partner at Multicoin Capital specializing in AI investments, joins Marc Weinstein of Mechanism Capital, Anand Iyer focusing on the post-AGI world, and Ed Roman from HackVC. They dive into how decentralized technologies can drive AI innovation and explore the critical role of tokens in AI networks. Topics include token design for sustainable growth, the relationship between value and speculation in AI tokens, and the challenges of integrating autonomous AI agents. The discussion illuminates the future of decentralized AI and crypto innovations.

In this episode, Eugene Borukhovich interviews Anand Iyer, Chief Strategy Officer of Welldoc, discussing the early days of Welldoc and the digital therapeutics industry. They talk about leveraging mobile platforms for personalized coaching, obtaining FDA clearance, demystifying digital therapeutics, potential exit strategies for digital health companies, and the transformative power of digital therapeutics in improving lives.

Anand Iyer, Founder of Canonical Crypo and angel investor, talks about the intersection of AI and blockchain, the importance of decentralization in AI growth, and the significance of fully homomorphic encryption. He also discusses the underwriting process for pre-seed investments, the role of AI agents, and the popularity of projects like FrenTech in the crypto space.

In this episode, Anand Iyer, Chief Strategy Officer of Welldoc, discusses the development and outcomes of Welldoc's BlueStar, a mobile prescription therapy for type 2 diabetes. They explore the potential for reversing diabetes, improving diabetes care through technology and data analysis, and the challenges of commercializing digital therapeutics. They also touch on the opportunities for improving healthcare through digital tools and data insights.